(Q38107677)

29 August 2017

title

Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors (English)

1 reference

29 August 2017

1 reference

Boris A Margulis

1

1 reference

29 August 2017

Vladimir Vigont

2

1 reference

29 August 2017

Vladimir F Lazarev

3

1 reference

29 August 2017

Elena V Kaznacheyeva

4

1 reference

29 August 2017

Irina V Guzhova

5

1 reference

29 August 2017

language of work or name

English

0 references

publication date

15 May 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

587

1 reference

29 August 2017

issue

13

1 reference

29 August 2017

page(s)

1997-2007

1 reference

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Analysis of SCA1, DRPLA, MJD, SCA2, and SCA6 CAG repeats in 48 Portuguese ataxia families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

The wide spectrum of spinocerebellar ataxias (SCAs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Mouse models of polyglutamine diseases: review and data table. Part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Polyglutamine toxicity in non-neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

The hunt for huntingtin function: interaction partners tell many different stories

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Diagnosis and management of early- and late-onset cerebellar ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Ataxia and hereditary disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Familial myoclonus epilepsy and choreoathetosis: hereditary dentatorubral-pallidoluysian atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

DRPLA transgenic mouse substrains carrying single copy of full-length mutant human DRPLA gene with variable sizes of expanded CAG repeats exhibit CAG repeat length- and age-dependent changes in behavioral abnormalities and gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Current status of treatment of spinal and bulbar muscular atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Interaction of ataxin-3 with huntingtin-associated protein 1 through Josephin domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Neuronal Ca(2+) dyshomeostasis in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Genetic ablation and chemical inhibition of IP3R1 reduce mutant huntingtin aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Signal transduction to the permeability transition pore.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Amyloid fibers are water-filled nanotubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Huntington's disease: from molecular pathogenesis to clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: Celiac Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Role of proteolysis in polyglutamine disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

An intriguing new lead on Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Sequestration of glyceraldehyde-3-phosphate dehydrogenase to aggregates formed by mutant huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Hunting-ton for New Proteases: MMPs as the New Target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

A polyglutamine expansion disease protein sequesters PTIP to attenuate DNA repair and increase genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Aggresome formation and neurodegenerative diseases: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Cellular mechanisms of protein aggregate propagation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Fibrillar structure and charge determine the interaction of polyglutamine protein aggregates with the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Protein homeostasis in models of aging and age-related conformational disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Identification of a candidate therapeutic autophagy-inducing peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Molecular chaperones in the cytosol: from nascent chain to folded protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Heat shock factors: integrators of cell stress, development and lifespan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Suppression of protein aggregation by chaperone modification of high molecular weight complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Targeting mutant huntingtin for the development of disease-modifying therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.05.022

10.1016/J.FEBSLET.2013.05.022

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference